Read by QxMD icon Read

ClinicoEconomics and Outcomes Research: CEOR

Lee S Schwartzberg, Lincy S Lal, Sanjeev Balu, Kim Campbell, Lee Brekke, Caitlin Elliott, Stephanie Korrer
Background: Filgrastim and other granulocyte colony-stimulating factors are recommended to decrease febrile neutropenia (FN) incidence among patients with nonmyeloid cancers undergoing chemotherapy. Data comparing biosimilar filgrastim-sndz with reference filgrastim (filgrastim-ref) are limited outside of clinical trials in the US. Objective: To compare the incidence of FN across chemotherapy cycles 1-6 between patients treated with filgrastim-sndz vs filgrastim-ref...
2018: ClinicoEconomics and Outcomes Research: CEOR
Giorgio L Colombo, Sergio Di Matteo, Chiara Martinotti, Steffen M Jugl, Praveen Gunda, Mariantonietta Naclerio, Giacomo M Bruno
Objective: Secukinumab, a fully human monoclonal IgG1 antibody that selectively neutralizes the proinflammatory cytokine IL-17A, has been approved in Europe in 2015 for the treatment of adult patients with moderate-to-severe plaque psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis (AS). This analysis assessed the budget impact of introduction of secukinumab to the Italian market for all three indications from the perspective of the Italian National Health Service. Materials and methods: A cross-indication budget impact model was developed and included biologic-treated adult patients diagnosed with psoriasis, PsA, and AS...
2018: ClinicoEconomics and Outcomes Research: CEOR
Marco DiBonaventura, Antonio Nicolucci, Henrik Meincke, Agathe Le Lay, Janine Fournier
Purpose: This study investigated the association between body mass index (BMI) and three comorbid conditions (type 2 diabetes [T2D], prediabetes, and hypertension) on humanistic and economic outcomes. Patients and methods: This retrospective observational study collected data from German (n=14286) and Italian (n=9433) respondents to the 2013 European Union National Health and Wellness Survey, a cross-sectional, nationally representative online survey of the general adult population...
2018: ClinicoEconomics and Outcomes Research: CEOR
Myrlene S Aigbogun, Sizhu Liu, Siddhesh A Kamat, Christophe Sapin, Amy M Duhig, Leslie Citrome
Objective: This study used a decision-analytic framework to assess the cost-effectiveness of brexpiprazole vs comparator branded therapies for reducing relapses and hospitalizations among adults with schizophrenia from a US payer perspective. Methods: An economic model was developed to assess patients with stable schizophrenia initiating treatment with brexpiprazole (1-4 mg), cariprazine (1-6 mg), or lurasidone (40-80 mg) over a 1-year period. After 6 months, patients remained on treatment or discontinued due to relapse, adverse events, or other reasons...
2018: ClinicoEconomics and Outcomes Research: CEOR
Jeffrey Vietri, Elizabeth T Masters, Alexandra I Barsdorf, Jack Mardekian
Objective: To provide per-patient estimates of the economic burden for opioid medication abuse with and without tampering. Patients and methods: Adults in the US who participated in the 2010 and/or 2011 National Health and Wellness Survey were resurveyed to provide information on use and abuse of prescription opioids in the previous 3 months. Participants (N=20,885) were categorized as those who abused and tampered (n=107), abused without tampering (n=118), those who reported using of opioids as prescribed (n=981), and non-opioid controls (n=19,679)...
2018: ClinicoEconomics and Outcomes Research: CEOR
Mariam Hassan, Machaon M Bonafede, Brendan L Limone, Paul Hodgkins, Gregory S Sawicki
Purpose: To conduct an analysis describing clinical characteristics, pulmonary exacerbation (PEx) events, and health care resource utilization among Medicaid-insured patients with cystic fibrosis (CF). Patients and methods: A retrospective analysis of the Truven Health MarketScan® Medicaid Multi-State administrative claims database (2010-2014) was undertaken. Patients aged ≥6 years with a CF diagnosis, continuously enrolled for 12 months, were identified. Demographics, comorbidities, PEx events, and health care resource utilization and costs over a 12-month enrollment period were analyzed for all patients and by age groups...
2018: ClinicoEconomics and Outcomes Research: CEOR
Enrico Torre, Giacomo Matteo Bruno, Sergio Di Matteo, Chiara Martinotti, Martina Oselin, Maria Chiara Valentino, Alessio Parodi, Luigi Carlo Bottaro, Giorgio Lorenzo Colombo
Background: Diabetes represents a relevant public health problem worldwide due to its increasing prevalence and socioeconomic burden. There is no doubt that tight glycemic control reduces the development of diabetic complications such as the long-term costs related to the disease. The aim of our model was to calculate total direct costs associated with the two treatments considered in DUAL VII study, and hence evaluate the potential economic benefits for the National Health System (NHS) deriving from the use of insulin degludec plus liraglutide (IDegLira) in a once-daily fixed combination...
2018: ClinicoEconomics and Outcomes Research: CEOR
Hang Cheng, Jeffrey W Clymer, Rana A Qadeer, Nicole Ferko, Behnam Sadeghirad, Chris G Cameron, Joseph F Amaral
Background: As compared to conventional techniques, recent meta-analyses have reported cost savings with Harmonic devices; however, only in thyroidectomy. Thus, the aim of this study was to evaluate the costs associated with Harmonic devices versus conventional techniques across a range of surgical procedures. Methods: A systematic search of MEDLINE, EMBASE, and Cochrane Library was conducted from inception to October 01, 2016 without language restrictions to identify randomized controlled trials comparing Harmonic devices to conventional techniques and reporting procedure costs (operating time plus operating equipment/consumables/device costs)...
2018: ClinicoEconomics and Outcomes Research: CEOR
Simona Cammarota, Anna Citarella, Lamberto Manzoli, Maria Elena Flacco, Giustino Parruti
Background: Due to the success of antiretroviral therapy, human immunodeficiency virus (HIV) infection has been transformed into a lifelong condition. In Italy, little is known about the impact of comorbidities (CMs) on the risk of hospitalization and related costs for people who live with HIV (PWLHIV). The objective of the study was to quantify the risk of hospitalization and costs associated with CMs in an Italian cohort of PWLHIV. Methods: The study population included subjects aged ≥18 years with HIV infection, identified in the Abruzzo's hospital discharge database among files stored from 2004 until 2013 and then followed up until December 2015...
2018: ClinicoEconomics and Outcomes Research: CEOR
Christine L Baker, Yao Ding, Cheryl P Ferrufino, Stacey Kowal, Jenen Tan, Prasun Subedi
Introduction: Smoking drives substantial direct health care spending, comprising 8.7% ($168 billion) of annual United States aggregated spending. Smoking cessation (SC) prescription use is an effective strategy to improve health outcomes, increase quit rates, and reduce economic burden. However, patient out-of-pocket costs may limit the use. Health care payers play a vital role in driving use through formulary decisions and copayment policies but must consider both the near-term financial investment as well as downstream effects of increased coverage on health care budgets...
2018: ClinicoEconomics and Outcomes Research: CEOR
Rao Fu, Jake Gundrum, Anita H Sung
Purpose: The objectives of this study were to present trends in posaconazole use over time and describe selected outcomes among patients at high risk of invasive fungal infections (IFIs) by use and type of antifungal medicine. Methods: A retrospective observational study using data from the Premier Healthcare Database between January 2007 and March 2016 was conducted. Inpatient use of posaconazole by formulation and year is described. Separately, four cohorts of patients at high risk of IFI - those with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), hematopoietic stem-cell transplantation (HSCT), and graft-vs-host disease (GVHD) - but without a diagnosis code for IFI during the index encounter were identified as potential candidates for antifungal prophylaxis...
2018: ClinicoEconomics and Outcomes Research: CEOR
Peter Douglas Klassen, Wellington K Hsu, Frederic Martens, Jason A Inzana, Wimar A van den Brink, Michael W Groff, Claudius Thomé
Introduction: Lumbar discectomy patients with large annular defects are at a high risk for reherniation and reoperation, which could be mitigated through the use of an annular closure device (ACD). To identify the most effective treatment pathways for this high-risk population, it is critical to understand the clinical outcomes and socioeconomic costs among reoperated patients as well as the utility of ACD for minimizing reoperation risk. Methods: This was a post hoc analysis of a prospective, multicenter, randomized controlled trial (RCT) designed to investigate the safety and efficacy of an ACD...
2018: ClinicoEconomics and Outcomes Research: CEOR
Zorica Naumovska, Aleksandra K Nestorovska, Aleksandra Grozdanova, Kristina Hristova, Aleksandar Dimovski, Ljubica Suturkova, Zoran Sterjev
Purpose: A rational use of statins has a major and increasing importance in public health and allocation of financial resources by the health insurance funds (HIFs). The aim of this study was to evaluate the market share and utilization trends of statins in the Republic of Macedonia (R. Macedonia) from 2013 to 2016. Materials and methods: A retrospective analysis and data comparison for the utilization of HMG-CoA inhibitors (C10AA) in R. Macedonia from 2013 to 2016 were conducted...
2018: ClinicoEconomics and Outcomes Research: CEOR
Vjollca Qerimi, Aleksandra Kapedanovska Nestorovska, Zoran Sterjev, Sonja Genadieva-Stavric, Ljubica Suturkova
Purpose: A decision-analytic model was developed to study the impact of induction regimens vincristine, adriamycin, dexamethasone (VAD); thalidomide, dexamethasone (TD); and bortezomib, dexamethasone (BorD), followed by autologous stem cell transplantation (ASCT) for treating multiple myeloma (MM) patients in Macedonia. Additionally, a cost-effectiveness analysis (CEA) of treatment sequences to predict health effects and costs of different treatment sequences was performed. Methods: Model strategies were based on a previously published study for treating patients with MM in Macedonia...
2018: ClinicoEconomics and Outcomes Research: CEOR
Signe Westmark, Dorte Melgaard, Line O Rethmeier, Lars Holger Ehlers
Objectives: To estimate the annual cost at the hospital and in the municipality (social care) due to dysphagia in geriatric patients. Design: Retrospective cost analysis of geriatric patients with dysphagia versus geriatric patients without dysphagia 1 year before hospitalization. Setting: North Denmark Regional Hospital, Hjørring Municipality, Frederikshavn Municipality, and Brønderslev Municipality. Subjects: A total of 258 hospitalized patients, 60 years or older, acute hospitalized in the geriatric department...
2018: ClinicoEconomics and Outcomes Research: CEOR
Wenjie Zhang, Tony B Amos, Stephen W Gutkin, Nicole Lodowski, Emma Giegerich, Kruti Joshi
Purpose: The aim of this study was to conduct a systematic literature review on the burden of schizophrenia in privately insured US patients. Materials and methods: A systematic literature review of English language peer-reviewed journal articles of observational studies published from 2006 to 2016 was conducted using EMBASE/MEDLINE databases. Abstracts covering substantial numbers of patients with schizophrenia or schizoaffective disorder (i.e., N ≥ 100) were included for full-text review...
2018: ClinicoEconomics and Outcomes Research: CEOR
Tiziana Galli, Paolo Mirata, Emanuela Foglia, Davide Croce, Emanuele Porazzi, Lucrezia Ferrario, Elena Ricci, Elisabetta Garagiola, Roberta Pagani, Giuseppe Banfi
Purpose: The aim of the present study was to compare 2 clinical assessment tools, the Modified Barthel Index (currently administered to patients admitted into inpatient rehabilitation units after elective hip or knee arthroplasty) with the World Health Organization Disability Assessment Schedule (WHODAS) 2.0 scale, in order to identify which tool is more suitable for assessing the disability and the "recovery rate". Patients and methods: A perspective multicenter observational study was developed, involving 2 hospital authorities in Italy...
2018: ClinicoEconomics and Outcomes Research: CEOR
Alistair S Curry, Shkun Chadda, Aurélie Danel, Douglas L Nguyen
Objectives: Gastrointestinal (GI) intolerance is associated with adverse outcomes in critically ill patients receiving enteral nutrition (EN). The objective of this analysis is to quantify the cost of GI intolerance and the cost implications of starting with semi-elemental EN in intensive care units (ICUs). Study design: A US-based cost-consequence model was developed to compare the costs for patients with and without GI intolerance and the costs with semi-elemental or standard EN while varying the proportion of GI intolerance cases avoided...
2018: ClinicoEconomics and Outcomes Research: CEOR
Erkki Soini, Ossi Riekkinen, Heikki Kröger, Petri Mankinen, Taru Hallinen, Janne P Karjalainen
Purpose: Osteoporosis is asymptomatic morbidity of the elderly which develops slowly over several years. Osteoporosis diagnosis has typically involved Fracture Risk Assessment (FRAX) followed by dual energy X-ray absorptiometry (DXA) in specialist care. Point-of-care pulse-echo ultrasound (PEUS) was developed to overcome DXA-related access issues and to enable faster fracture prevention treatment (FPT) initiation. The objective of this study was to evaluate the cost-effectiveness of two proposed osteoporosis management (POMs: FRAX→PEUS-if-needed→DXA-if-needed→FPT-if-needed) pathways including PEUS compared with the current osteoporosis management (FRAX→DXA-if-needed→FPT-if-needed)...
2018: ClinicoEconomics and Outcomes Research: CEOR
Brooke A Spaeth, Billingsley Kaambwa, Mark Ds Shephard, Rodney Omond
Aim: To determine the cost-effectiveness of utilizing point-of-care testing (POCT) on the Abbott i-STAT device as a support tool to aid decisions regarding the emergency medical retrievals of patients at remote health centers in the Northern Territory (NT) of Australia. Methods: A decision analytic simulation model-based economic evaluation was conducted using data from patients presenting with three common acute conditions (chest pain, chronic renal failure due to missed dialysis session(s), and acute diarrhea) at six remote NT health centers from July to December 2015...
2018: ClinicoEconomics and Outcomes Research: CEOR
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"